Takeaway

• The US Food and Drug Administration (FDA) has withdrawn the approval of umbralisib after an investigation suggested a "possible increased risk of death."

Key points

• Umbralisib had received accelerated approval from the FDA in February 2021 for the treatment of adults with relapsed or refractory marginal zone lymphoma who...